Takeda taps Enterome for microbiome R&D

Japanese drugmaker Takeda is deepening its work in microbiomics, signing a drug discovery deal with France's Enterome Bioscience in hopes of spotlighting new treatments for gastrointestinal disorders. Under the agreement, Takeda is handing its partner an undisclosed upfront payment and promising three years of R&D funding plus milestone cash tied to the progression of drug candidates. The goal is to treat inflammatory bowel diseases and motility disorders by modulating the billions of organisms in the human gut. Release

Read more on